Cyberattacks against accounting software firm Wolters Kluwer and the City of Baltimore in May showed how the newest wave of malicious hacking can have significant, often...Technologyread more
The European parliamentary election is the second largest democratic exercise in the world.Europe Newsread more
Biden had criticized Kim Jong Un as a "dictator" and a "tyrant" at a recent rally in Philadelphia. North Korean state media responded by calling Biden a "fool of low IQ" among...Politicsread more
Buybacks have gotten a bad rap from both Republicans and Democrats. But stocks would be trading at a massive discount without them.Marketsread more
Microsoft shares have gained 133% since November 2015, outperforming a tech "basket of unicorns" over that stretch.Technologyread more
The president's state visit comes amid tensions with carmaker Toyota over potential auto tariffs. Trump has repeatedly threatened Japanese and European carmakers with tariffs.Traderead more
The IRS is about to release a new draft of Form W-4, which will more closely reflect the changes stemming from the Tax Cuts and Jobs Act. For workers, that means they'll need...Personal Financeread more
The Mega Millions jackpot has spilled over $400 million. It would be the ninth largest winning since the game began in 2002.Personal Financeread more
Trump was speaking at a meeting of Japanese business leaders in Tokyo during his state visit to Japan on Saturday.Marketsread more
The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
When commercial real estate investor Manny Khoshbin spent $2.2 million on the fastest production car in the world, he had no idea it would very quickly also become the...Autosread more
Esperion's experimental treatment for lowering cholesterol is poised to help millions of patients, CEO Tim Mayleben told CNBC on Wednesday.
Earlier this week, the company announced its drug, bempedoic acid, reduced bad cholesterol — known as LDL — by 18 percent in a clinical trial. The treatment was used on top of statins, the medicine commonly used to treat high cholesterol.
Mayleben said the idea is to help those who are taking a statin or the maximum dose of a statin that they can tolerate and are not getting their LDL to their goal.
"There is a problem with tolerability with statins, and what we've seen so far in our clinical studies is that bempedoic acid doesn't seem to cause the same muscle aches and pains that statins have been known for," he said in an interview with CNBC's Meg Tirrell on "Power Lunch. "
"We know [our new drug] can get 6 or 7 million patients to their goal."
Shares of Esperion popped on the news. The stock is up more than 10 percent since Monday.
About 1 in 3 Americans have high cholesterol, which raises the risk for heart disease and stroke. Both are leading causes of death in the U.S.
Some patients need a class of drugs called PCSK9 inhibitors, which have been shown to dramatically lower LDL levels but tend to be pricey.
However, Mayleben said his company is developing a new drug that can complement statins "for the many, not for the few patients ... who need a specialty drug like PCSK9s."
"Our drugs are really positioned for the many patients, the millions of patients who are taking the maximum dose of a statin they can take but still need additional LDL cholesterol lowering, and in some cases that's no statin at all," he said.
"For those patients we have a convenient, once-daily pill that they can use and get their cholesterol down to their targeted goal."